Navigation Links
Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results
Date:5/27/2009

CAMBRIDGE, Mass., May 27 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has entered into a research collaboration with the University of California San Francisco Cancer Center (UCSF) aimed at accelerating cancer research and drug development across several therapeutic areas. This collaboration will combine the clinical and research oncology expertise of UCSF with the computational expertise and supercomputer-driven REFS(TM) platform of GNS. Financial terms of the agreement were not disclosed.

GNS and UCSF have utilized REFS(TM) to discover and validate novel mediators of the cell cycle transition, which is a critical determinant of the rate of cancer cell proliferation and tumor growth. These results were presented by UCSF researcher Dr. Rina Gendelman, a post-doctoral fellow in Dr. W. Michael Korn's laboratory, at the American Association for Cancer Research 2009 meeting on April 18-22 in Denver, during which Dr. Gendelman received an AACR-Susan G. Komen Scholar-in-Training Award. GNS and prominent UCSF investigators Dr. Joe Gray, Dr. Frank McCormick, and Dr. W. Michael Korn will continue the collaboration through a number of additional projects.

Dr. Korn, who is an Associate Professor at UCSF, will lead the UCSF-GNS research partnership.

The parties will continue with research to elucidate the RAS-MAPK and PI3K cancer pathways, pathways critical for initiation and progression of many cancers, by building models of breast, pancreatic, and esophageal cancer based on data from ongoing research at UCSF using the REFS(TM) platform and simulation of these models. The discoveries from the ongoing research are expected to include potential novel drug targets in those cancer types.

"GNS is excited to be working with UCSF, a world-class research and clinical institution, to tackle key current issues in cancer research," said Dr. Iya Khalil, Executive Vice President and co-founder of GNS. "Our collaborative work with UCSF is one of several examples of GNS's applying our supercomputer-driven REFS(TM) platform to accelerate better treatments for patients with cancer."

About Gene Network Sciences

Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) technology in pharmaceutical and clinical settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

About UCSF

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

UC Disclaimer

The information stated above was prepared by Gene Network Sciences, Inc., to report the outcome of research involving its product and reflects solely the opinion of GNS. Nothing in this statement shall be construed to imply any support or endorsement of GNS, or any of its products, by The Regents of the University of California, its officers, agents and employees.


'/>"/>
SOURCE Gene Network Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharma and Biotech Companies Plug into Singapores Integrated Research Network
2. HealthCore Responds to Need for Real-world Health Outcomes Information on Drugs and Devices with Physician Network and Prospective Effectiveness Research
3. Healthy Advice Networks Achieves Strong Growth Despite Challenging Economy
4. Chimerix Joins International Network of Organizations to Cure Malaria
5. Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network
6. NeoStem Expands Stem Cell Collection Center Network Into New Jersey Led by Leading Plastic Surgeon and Anti-Aging Authority
7. Agencies Unite to Launch Donor Network Alliance: First-Ever Web-Based Collective of Egg Donor Candidates
8. Gene Network Sciences Announces Michael Gilman as Board Member
9. UKs Institute of Cancer Research and Silicon Graphics Establish Long-Term Alliance to Design and Outfit World-Class Network Biology Lab
10. Yongye Biotechnology International to Expand its Network of Branded Stores
11. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider ... that its board of directors has amended its shareholder rights plan. The ... 2017 to March 27, 2018. The amendment was not in response to ... ... Ltd. is a China -based biopharmaceutical company that ...
(Date:3/23/2017)... ... ... to announce it has become the premiere team-building cooking event company in San Diego. ... as Illumina, HP and Qualcomm, and is ranked #1 in its category on Trip Advisor. ... new team building format, a way for teams to not only interact with one another ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
Breaking Biology Technology:
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... Used combined in one project, multi-biometric ... ...
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
Breaking Biology News(10 mins):